NASDAQ · ANL
Adlai Nortye Ltd.
$10.28+$0.08 (+0.78%)
Adlai Nortye Ltd.’s quoted price sits in the upper half of its reported 52-week range, 40.41% below the high.
Loading market information…
NASDAQ · LPCN · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Lipocine Inc.’s quoted price sits in the lower half of its reported 52-week range, 87.71% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Lipocine Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$0.39. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Lipocine Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for pharmaceutical compounds that typically suffer from low bioavailability. Its foremost investigational therapy is TLANDO, an oral solution for testosterone replacement. The company's development pipeline also encompasses several other promising candidates: LPCN 1144: An orally administered prodrug derived from bioidentical testosterone, which has successfully completed Phase II clinical trials for the treatment of non-cirrhotic non-alcoholic steatohepatitis. LPCN 1111: An oral prodrug of testosterone tridecanoate, engineered for once-daily administration, and having also concluded Phase II clinical studies in men experiencing hypogonadism. LPCN 1148: A novel prodrug combining testosterone and testosterone laurate, designed for the management of decompensated cirrhosis. LPCN 1154: An investigational new drug application has been submitted to initiate a Phase 2 study targeting Postpartum Depression. LPCN 2101: A compound intended for women with epilepsy, which has progressed beyond its pre-clinical study phase. LPCN 1107: An oral hydroxyprogesterone caproate product, which has completed its dose-finding Phase II clinical trial aimed at preventing recurrent preterm birth. The corporate headquarters for Lipocine Inc. are located in Salt Lake City, Utah.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:17 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 8, 2025 |
| -$0.350.0% vs estimate |
| $93.86K-73.33% vs estimate |
| Q4 2024 | Mar 13, 2025 | $0.33+182.5% vs estimate | $3.49M+33.57% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | -$0.44+8.33% vs estimate | $0.00-100.0% vs estimate |
|---|
THE ANALYST VIEW
9 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $4.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$10.28+$0.08 (+0.78%)
Adlai Nortye Ltd.’s quoted price sits in the upper half of its reported 52-week range, 40.41% below the high.
$11.08+$0.01 (+0.09%)
ProMIS Neurosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.56% below the high.
$2.70+$0.14 (+5.47%)
Edesa Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 86.71% below the high.
$2.02+$0.02 (+1.0%)
BioLineRx Ltd.’s quoted price sits in the lower half of its reported 52-week range, 48.86% below the high.
$8.72-$0.03 (-0.29%)
Moleculin Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.23% below the high.
$0.03-$0.00 (-9.41%)
Adaptimmune Therapeutics plc’s quoted price sits in the lower half of its reported 52-week range, 92.73% below the high.
$0.12$0.00 (0.0%)
OSR Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 87.17% below the high.
$2.11+$0.13 (+6.57%)
Ernexa Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.6% below the high.
